Arkadios Wealth Advisors Invests $550,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Arkadios Wealth Advisors bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,799 shares of the specialty pharmaceutical company’s stock, valued at approximately $550,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $25,000. Financial Management Professionals Inc. bought a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $30,000. Versant Capital Management Inc increased its position in Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $42,000. Finally, Headlands Technologies LLC increased its position in Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,015 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $37.05 on Tuesday. The stock has a 50 day moving average price of $32.74 and a two-hundred day moving average price of $33.33. The firm has a market capitalization of $2.07 billion, a P/E ratio of 33.38 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52 week low of $27.05 and a 52 week high of $40.28.

Wall Street Analysts Forecast Growth

SUPN has been the subject of a number of research analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Cantor Fitzgerald raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price objective for the company in a report on Wednesday, July 30th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.